Clinical Trial Details

DAPHNe: De-escalation to adjuvant antibodies post-pCR to Neoadjuvant THP (paclitaxel/trastuzumab/pertuzumab) - a pilot study in HER-2 positive breast cancer (DF/HCC 18-394)

This research study is studying whether participants and their doctors are willing to determine post-surgery treatment on the basis of response to pre-surgery treatment, and studying blood and tissue collected from participants treated with a combination of drugs as a treatment for breast cancer.

The names study drugs involved in this study are:

  • Paclitaxel (also called Taxol)
  • Trastuzumab (also called Herceptin)
  • Pertuzumab (also called Perjeta)

Learn More

Principal Investigator(s)


Mary Miller, LPN at 203-358-8879 or [email protected]


Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.